Oligonucleotide-based inhibition of embryonic gene expression

Nature Biotechnology

Volumn 17, Issue 12, 1999, Pages 1184-1187

  Driver, Samuel E ^a   Robinson, Gregory S ^a   Flanagan, Jean ^b   Shen, Wei ^c   Smith, Lois E H ^c   Thomas, David W ^d   Roberts, Peter C ^e  

^a Q1K Technology Inc   (United States)

^b Ontogeny Inc   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d Tanox Biosystems Inc   (United States)

^e GENZYME CORPORATION   (United States)

Author keywords

Angiogenesis; Antisense; Development; Gene function; Knockout; Oligonucleotide

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; UVOMORULIN; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; BIOTECHNOLOGY; EMBRYO; EMBRYO DEVELOPMENT; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; KNOCKOUT GENE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 0032765051     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/70724     Document Type: Article

References (35)

1. Christoffersen, R.E. Translating genomics information into therapeutics: a key role for oligonucleotides. Nat. Biotechnol. 15, 483-484 (1997).
2. Juliano, R.L, Alahari, S., Yoo, H., Kole, R. & Cho, M. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. 16, 494-502 (1999).
3. Nyce, J.W. Insight into adenosine receptor function using antisense and geneknockout approaches. Trends. Pharmacol. Sci. 20, 79-83 (1999).
4. Jones, D.A. & Fitzpatrick, F.A. Genomics and the discovery of new drug targets. Curr. Opin. Chem. Biol. 3, 71-76 (1999).
5. Bramlage, B., Luzi, E. & Eckstein, F. Designing ribozymes for the inhibition of gene expression. Trends. Biotechnol. 16, 434-438 (1998).
6. Dickinson, L.A. et al. Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc. Natl. Acad. Sci. USA. 95, 12890-12895 (1998).
7. Mei, H.Y. et al. Discovery of selective, small-molecule inhibitors of RNA complexes - I. The Tat protein/TAR RNA complexes required for HIV-1 transcription. Bioorg. Med. Chem. 5, 1173-1184 (1997).
8. Tatton, W.G., Chalmers-Redman, R.M., Ju, W.Y., Wadia, J. & Tatton, N.A. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J. Neural. Transm. Suppl. 49, 245-268 (1997).
9. Wodarz, A. & Nusse, R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Biol. 14, 59-88 (1998).
10. Lai, L.W. & Lien, Y.H. Homologous recombination based gene therapy. Exp. Nephrol. 7, 11-14 (1999).
11. Osterrieder, N. & Wolf, E. Lessons from gene knockouts. Rev. Sci. Tech. 17, 351-364 (1998).
12. Sauer, B. Inducible gene targeting in mice using the Cre/lox system. Methods 14, 381-392 (1998).
13. Hynes, R.O. Targeted mutations in cell adhesion genes: what have we learned from them? Dev. Biol. 180, 402-412 (1996).
14. Hynes, R.O. & Bader, B.L. Targeted mutations in integrins and their ligands: their implications for vascular biology. Thromb. Haemostasis. 78, 83-87 (1997).
15. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996).
16. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442 (1996).
17. Robinson, G.S. et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. USA. 93, 4851-4856 (1996).
18. Smyth, A.P., Rook, S.L., Detmar, M. & Robinson, G.S. Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes. J. Invest. Dermatol. 108, 523-526 (1997).
19. Chen, B. & Hales, B.F. Antisense oligonucleotide down-regulation of E-cadherin in the yolk sac and cranial neural tube malformations. Biol. Reprod. 53, 1229-1238 (1995).
20. Gaudette, M.F., Hampikian, G., Metelev, V., Agrawal, S. & Crain, W.R. Effect on embryos of injection of phosphorothioate-modified oligonucleotides into pregnant mice. Antisense. Res. Dev. 3, 391-397 (1993).
21. Bourque, A.J. & Cohen, A.S. Quantitative analysis of phosphorothioate oligonucleotides in biological fluids using direct injection fast anion-exchange chromatography and capillary gel electrophoresis. J. Chromatogr. Biomed. Appl. 662, 343-349 (1994).
22. Zhao, Q. et al. Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice. Antisense. Nucleic. Acid. Drug Dev. 8, 451-458 (1998).
23. Pacifici, G.M. & Nottoli, R. Placental transfer of drugs administered to the mother. Clin. Pharmacokinet. 28, 235-269 (1995).
24. Yu, D. et al. Hybrid oligonucleotides: synthesis, biophysical properties, stability studies, and biological activity. Bioorg. Med. Chem. 4, 1685-1692 (1996).
25. Guvakova, M.A., Yakubov, L.A., Vlodavsky, I., Tonkinson, J.L. & Stein, C. A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620-2627 (1995).
26. Rockwell, P. et al. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 94, 6523-6528 (1997).
27. Takeichi, M. et al. Cadherins in brain patterning and neural network formation. Cold Spring Harb. Symp. Quant. Biol. 62, 505-510 (1997).
28. Anderson, H. Adhesion molecules and animal development. Experientia 46, 2-13 (1990).
29. Senger, D.R. et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12, 303-324 (1993).
30. Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237, 1-30 (1999).
31. Aiello, L.P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480-1487 (1994).
32. Baumgartner, I. & Isner, J.M. Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF). Vasa. 27, 201-206 (1998).
33. Grunstein, J., Roberts, W.G., Mathieu-Costello, O., Hanahan, D. & Johnson, R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 59, 1592-1598 (1999).
34. Kitamoto, Y., Tokunaga, H. & Tomita, K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J. Clin. Invest. 99, 2351-2357 (1997).
35. Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J. & Rutter, W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18, 5294-5299 (1979).